David H. Fater, CEO of Vicor Technologies, Inc., announced that Drs. Daniel Weiss and Jerry Anchin, Vicor’s Chief Medical Officer and Director of Research and Development, respectively, participated in the start of a new cardiac screening initiative being conducted by Cardiac Risk in the Young (CRY), a London-based non-profit organization. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Specifically, Drs. Weiss and Anchin trained technicians in the use of the company’s PD2i® nonlinear algorithm and supervised initial data collection efforts. Approximately thirty 14-year-olds were tested with the PD2i® nonlinear algorithm. The multi-year CRY initiative will offer free cardiac screening to 14-year-olds (DOB 1995); 14 is the earliest post-puberty age for which proactive screening is considered valuable. Participants will then be tested annually through age 19. In addition to identifying those youngsters who are at elevated risk of sudden cardiac death for referral for further evaluation, a goal of the study is to assess the changes that occur in those risk factors through the teenage years. Approximately 600 young people are struck down by sudden cardiac death annually in the UK. Ten percent of the estimated seven million individuals fitting this description are expected to participate.

Dr. Sanjay Sharma, the consulting cardiologist spearheading the initiative, selected Vicor’s PD2i® nonlinear algorithm for use in the CRY screening initiative. The ultimate goal of the screening initiative is to improve the accuracy of identifying teenagers at elevated risk of sudden cardiac death in the future.

“We’re delighted by the level of enthusiasm the CRY staff showed for the PD2i®. Initially, the technicians were hesitant about including the PD2i® test in their screening regimen because they were unfamiliar with it. Once they discovered how easy to use it is – by lunch time of the first day – they were very excited to be using the PD2i®, a tool that, they said, adds tremendous value to their efforts by enabling a risk prognostic. The CRY screening initiative is an incredibly well-organized and professionally-run operation. No doubt it will be a great success in furthering understanding of cardiac death in the young,” stated Dr. Anchin.

The CRY screening initiative takes place two weekends per month at the Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George's Healthcare NHS Trust. Azra Loncarevic-Srmic, project manager, oversees three ECG technicians, an echocardiogram technician, a resident cardiologist, and two schedulers. According to Ms. Loncarevic-Srmic, they anticipate screening 300 participants per weekend.

“We're honored to have our PD2i® nonlinear algorithm selected for use in this important initiative. Given the consistently accurate results achieved, to date, with the PD2i® nonlinear algorithm in risk stratifying adults at risk of sudden cardiac death, we're confident that the PD2i® nonlinear algorithm will prove beneficial in identifying youths in need of treatment to prevent a cardiac episode," stated Mr. Fater.

Dr. Sharma is Professor of the recently-created Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George's Healthcare NHS Trust. The Inherited Cardiovascular Disease and Sports Cardiology Centre is the world's first specialist, multi-disciplinary facility dedicated to providing services to populations – those between the ages of 14 and 35, including families and athletes - affected by or at risk for sudden cardiac death. St. George's is one of England's largest teaching hospitals and the first hospital in the United Kingdom to develop a specialist clinic for young sudden cardiac death after receiving CRY's donation of echocardiogram equipment. CRY was founded in 1996 to raise awareness of conditions that can lead to sudden cardiac death and sudden cardiac death syndrome in those between the ages of 14 and 35. Additional information about CRY may be found at http://www.c-r-y.org.uk/.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer:The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Institute for Surgical Research, the Department of the Army, Department of Defense, the U.S. Government, or CRY of the information, products or services contained therein.